Non-small cell lung cancer (NSCLC) is the most common form, accounting for approximately 85% of all lung cancers.2 Many people diagnosed with early-stage NSCLC have surgery to remove the cancer; however, for approximately half of these patients, the cancer unfortunately returns.3 Experts agree there is an urgent need for enhanced screening uptake — which has hovered around five percent in recent years amongst those eligible to receive it4 — as well as improved treatment options in early-stage NSCLC to help prevent devastating cancer recurrences.

Studies have shown that treatments beyond chemotherapy, including targeted therapy and now immunotherapy – a type of personalized cancer treatment that activates the immune system to fight cancer – may help improve outcomes for certain patients with early-stage NSCLC after surgery.5 What’s promising is that these studies have now led to U.S. Food and Drug Administration approvals in the post-surgery setting to help reduce the risk of recurrence for patients with specific types of early-stage NSCLC, introducing a new era for these lung cancer patients.

Dr. David Carbone, Professor of Internal Medicine and Director of the James Thoracic Oncology Center at Ohio State University Medical Center will discuss the latest progress, including one of the most recent developments in early-stage lung cancer for patients.

Interview courtesy: Genentech

1 ACS. Key Statistics for Lung Cancer. 2022. Accessed from: https://www.cancer.org/cancer/lung-cancer/about/key-statistics.html.
2 Molina et al. Non-Small Cell Lung Cancer: Epidemiology, Risk Factors, Treatment, and Survivorship. Mayo Clin Proc. 2008 May; 83(5): 584–594. Accessed September 27, 2021.
3 Yano T, Okamoto T, Fukuyama S, Maehara Y. Therapeutic strategy for postoperative recurrence in patients with non-small cell lung cancer. World J Clin
Oncol. 2014;5(5):1048-1054. doi:10.5306/wjco.v5.i5.1048
4 Fedewa SA, Kazerooni EA, Studts JL, et al. State Variation in Low-Dose CT Scanning for Lung Cancer Screening in the United States. JNCI: The Journal of the National Cancer Institute. doi: 10.1093/jnci/djaa170
5 Zappa et al. Non-small cell lung cancer: current treatment and future advances. Transl Lung Cancer Res. 2016 Jun; 5(3): 288–300. doi:
10.21037/tlcr.2016.06.07.

#davidcarbone #lungcancer #genentech #americancancersociety #factsfigures #disease #aminotherapy #etizolam #go2foundation #nsclc #surgery #chemotherapy #medicine #treatments #patients

The post EXCITING PROGRESS IN DIAGNOSING AND TREATING EARLY-STAGE LUNG CANCER appeared first on Good News!.

NEW RESEARCH FROM PROMINENT CANCER MEETING FOR THOSE WITH LUNG CANCER

People with Lung Cancer, Like Others with Serious Underlying Medical Conditions
Might Be at an Increased Risk for Severe Illness from COVID-19

Lung cancer is the second most common cancer in both men and women. This year, an estimated 228,820 adults (116,300 men and 112,520 women) in the United States will be diagnosed.

The fight against lung cancer continues with new research and scientific advances, including cancer experts investigating potential ways to treat the disease in earlier stages. Some of these latest findings in non-small cell lung cancer (NSCLC), including investigational studies in earlier stages of the disease, were presented at the American Society of Clinical Oncology ASCO20 Virtual Scientific Program.

Roy S. Herbst, MD, PhD of Yale Cancer Center and Smilow Cancer Hospital talks on the latest news from ASCO in the fight against lung cancer.

Lung cancer makes up almost 25% of all cancer deaths. There are two main types of lung cancer: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). NSCLC is the most common type of lung cancer. In fact, about 80%-85% of lung cancer cases are NSCLC. About 40% of patients are diagnosed at a later stage of disease, such as Stage IV, when the cancer has progressed to other organs. Approximately 10-15% of NSCLC patients in the US and Europe, and 30-40% of patients in Asia have EGFRm NSCLC. The prevalence of EGFR mutations in early stage are estimated to be ~33% in a global NSCLC population.

Interview courtesy: AstraZeneca
#roy #harbst #yale #cancer #center #smilow #covid-19 #covid #19 #covid19 #lung #severe #illness #medical #risk #diagnosed #research #scientific #advances #disease #cell #nsclc #american #society #clinical #oncology #asco #virtual #hospital #astrazeneca

The post NEW RESEARCH FOR LUNG CANCER appeared first on Good News!.